|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Transplantation in autoimmune liver diseases显示文摘Liver transplantation remains an effective treatment for those with end-stage disease and with intractable liver-related symptoms.The shortage of organs for transplantation has resulted in the need for rationing.A variety of approaches to selection and allocation have been developed and vary from country to country.The shortage of donors has meant that new approaches have to be adopted to make maximal use of the available organs;these include splitting grafts,use of extended criteria livers,livers from non-heart-beating donors and from living donors.Post transplantation,most patients will need life-long immunosuppression,although a small proportion can have immunosuppression successfully withdrawn.Newer immunosuppressive drugs and different strategies may allow a more targeted approach with a reduction in side-effects and so improve the patient and graft survival.For autoimmune diseases,transplantation is associated with significant improvement in the quality and length of life.Disease may recur after transplantation and may affect patient and graft survival. | Marcus Mottershead James Neuberger | 2008 | World Journal of Gastroenterology2008，14，21： | 4 |
| 2 | Donor transmitted and de novo cancer after liver transplantation显示文摘Cancers in solid organ recipients may be classified as donor transmitted,donor derived,de novo or recurrent.The risk of donor-transmitted cancer is very low and can be reduced by careful screening of the donor but cannot be abolished and,in the United Kingdom series is less than 0.03%.For donors with a known history of cancer,the risks will depend on the nature of the cancer,the interventions given and the interval between diagnosis and organ donation.The risks of cancer transmission must be balanced against the risks of death awaiting a new graft and strict adherence to current guidelines may result increased patient death.Organs from selected patients,even with high-grade central nervous system(CNS)malignancy and after a shunt,can,in some circumstances,be considered.Of potential donors with non-CNS cancers,whether organs may be safely used again depends on the nature of the cancer,the treatment and interval.Data are scarce about the most appropriate treatment when donor transmitted cancer is diagnosed:sometimes substitution of agents and reduction of the immunosuppressive load may be adequate and the impact of graft removal should be considered but not always indicated.Liver al-lograft recipients are at increased risk of some de novo cancers,especially those grafted for alcohol-related liver disease and hepatitis C virus infection.The risk of lymphoproliferative disease and cancers of the skin,upper airway and bowel are increased but not breast.Recipients should be advised to avoid risk behavior and monitored appropriately. | Rajeev Desai James Neuberger | 2014 | World Journal of Gastroenterology2014，20，20： | 3 |
| 3 | Cardiovascular morbidity and mortality after orthotopic liver transplantation显示文摘 | Simon D. Johnston Joan K. Morris Rob Cramb Bridget K. Gunson James Neuberger | 2002 | Transplantation2002，，6： | 2 |
| 4 | Autoimmune liver disease, autoimmunity and liver transplantation显示文摘 | Marco Carbone James M. Neuberger | 2014 | Journal of Hepatology2014，，： | 2 |
| 5 | Cancer Transmission From Organ Donors—Unavoidable But Low Risk显示文摘 | Rajeev Desai Dave Collett Christopher J. Watson Philip Johnson Tim Evans James Neuberger | 2012 | Transplantation Journal2012，，12： | 2 |
| 6 | How regenerative medicine and tissue engineering may complement the available armamentarium in gastroenterology?显示文摘The increasing shortage of donors and the adverse effects of immunosuppression have restricted the impact of solid organ transplantation.Despite the initial promising developments in xenotransplantation,roadblocks still need to be overcome and this form of organ support remains a long way from clinical practice.While hepatocyte transplantation may be effectively correct metabolic defects,it is far less effective in restoring liver function than liver transplantation.Tissue engineering,using extracellular matrix scaffolds with an intact but decellularized vascular network that is repopulated with autologous or allogeneic stem cells and/or adult cells,holds great promise for the treatment of failure of organs within gastrointestinal tract,such as endstage liver disease,pancreatic insufficiency,bowel failure and type 1 diabetes.Particularly in the liver field,where there is a significant mortality of patients awaiting transplant,human bioengineering may offer a source of readily available organs for transplantation.The use of autologous cells will mitigate the need for long term immunosuppression thus removing a major hurdle in transplantation. | Marco Carbone Jan Lerut James Neuberger | 2012 | World Journal of Gastroenterology2012，18，47： | 2 |
| 7 | Reducing the Risks of Cardiovascular Disease in Liver Allograft Recipients显示文摘 | George Mells James Neuberger | 2007 | Transplantation2007，，9： | 2 |
| 8 | Splitting livers – balancing the gain and the pain显示文摘 | Dave Collett John O’Neill James Neuberger | 2007 | Transplant International2007，，3： | 1 |
| 9 | The impact of disease recurrence on graft survival following liver transplantation: a single centre experience显示文摘 | Ian A Rowe Kerry Webb Bridget K Gunson Naimish Mehta Sayeed Haque James Neuberger | 2008 | Transplant International2008，，5： | 1 |
| 10 | Living liver donation: a survey of the attitudes of the public in Great Britain显示文摘 | James Neuberger Lauren Farber Michelle Corrado Claire O’Dell | 2003 | Transplantation2003，，8： | 1 |
| 11 | Long‐term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation显示文摘 | Michael R. Lucey Norah Terrault Lolu Ojo J. Eileen Hay James Neuberger Emily Blumberg Lewis W. Teperman | 2012 | Liver Transpl2012，，1： | 1 |
| 12 | A bioartificial liver-state of the art显示文摘 | Alastair J Strain James M Neuberger | 2002 | Science2002，295，： | 1 |
| 13 | Guidelines for selection of patients for liver transplantation in the era of donor-organ shortage显示文摘 | James Neuberger Oliver James | 1999 | The Lancet . 1999 (9190)1999，，9190： | 1 |
| 14 | Primary biliary cirrhosis显示文摘 | James Neuberger | 1997 | The Lancet1997，，9081： | 1 |
| 15 | Autoimmune Hepatitis and Liver Transplantation: Indications, Results, and Management of Recurrent Disease显示文摘 | Dhiraj Tripathi James Neuberger | 2009 | Semin Liver Dis2009，，03： | 1 |
| 16 | Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis显示文摘 | Alonso Vera Bridget K. Gunson Val Ussatoff Peter Nightingale Daniel Candinas Simon Radley A. David Mayer John A.C. Buckels Paul McMaster James Neuberger Darius F. Mirza | 2003 | Transplantation2003，，12： | 1 |
| 17 | Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) Results of Protocol E1293显示文摘 | Avi I. Einzig DOnna Neuberg Scot C. Remick Daniel D. Karp Peter J. O’Dwyer James A. Stewart Al B. Benson | 1996 | Medical Oncology1996，，2： | 1 |
| 18 | Incidence of Cancers Following Orthotopic Liver Transplantation in a Single Center: Comparison with National Cancer Incidence Rates for England and Wales显示文摘 | Ye H. Oo Bridget K. Gunson Robert J. Lancashire Kar K. Cheng James M. Neuberger | 2005 | Transplantation2005，，6： | 1 |
| 19 | Retransplantation for graft failure in chronic hepatitis C infection: A good use of a scarce resource?显示文摘AIM: To investigate the outcome of patients with hepatitis C virus (HCV) infection undergoing liver retransplantation. METHODS: Using the UK National Registry, patients undergoing liver transplantation for HCV-related liver disease were identified. Data on patient and graft characteristics, as well as transplant and graft survival were collected to determine the outcome of HCV patients undergoing retransplantation and in order to identify factors associated with transplant survival. RESULTS: Between March 1994 and December 2007, 944 adult patients were transplanted for HCV-related liver disease. At the end of follow-up, 617 of these patients were alive. In total, 194 (21%) patients had first graft failure and of these, 80 underwent liver retransplantation, including 34 patients where the first graft failed due to recurrent disease. For those transplanted for HCV-related disease, the 5-year graft survival in those retransplanted for recurrent HCV was 45% [95% confidence interval (CI): 24%-64%] compared with 80% (95% CI: 62%-90%) for those retransplanted for other indications (P = 0.01, log-rank test); the 5-year transplant survival after retransplantation was 43% (95% CI: 23%-62%) and 46% (95% CI: 31%-60%), respectively (P = 0.8, log-rank test). In univariate analysis of all patients retransplanted, no factor analyzed was significantly associated with transplant survival. CONCLUSION: Outcomes for retransplantation in patients with HCV infection approach agreed criteria for minimum transplant benefit. These data support selective liver retransplantation in patients with HCV infection. | Ian A Rowe Kerri M Barber Rhiannon Birch Elinor Curnow James M Neuberger | 2010 | World Journal of Gastroenterology2010，16，40： | 1 |
| 20 | Autoimmune liver diseases and recurrence after orthotopic liver transplantation: what have we learned so far?显示文摘 | Tim C. M. A. Schreuder Stefan G. Hübscher James Neuberger | 2008 | Transplant International2008，，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员